Longevity and Aging: A New Approach Using Metformin

Medical Intervention to Slow Aging

Dr. Nir Barzilai, Director of the Institute for Aging Research at Albert Einstein College of Medicine, and a group of researchers from the American Federation for Aging Research (AFAR) are working to validate metformin as the first-ever anti-aging medication.⁶ Metformin is a widely-used antidiabetic treatment that has also been shown to increase the production of known longevity-promoting signaling molecules in cells.⁶ This drug favorably influences biological outcomes that are associated with the development of age-related conditions including inflammation, oxidation, diminished autophagy and cellular senescence.⁷ Autophagy is the natural, destructive mechanism that disassembles unnecessary or dysfunctional components. It allows the orderly degradation and recycling of cellular components.

Dr. Nir said, “We would rather prevent aging, and by that, prevent the onset of multiple diseases.”⁸ Craig Currey, a lead researcher at Cardiff University, also found that metformin already demonstrated positive results in treating cancer and cardiovascular diseases in addition to treating diabetes.⁸ Metformin helps control diabetes by increasing insulin sensitivity and decreasing production of glucose in the liver.⁹ Metformin also benefits cells in the human body by increasing oxygen molecules released into a cell.⁸  Non-human studies demonstrated metformin’s ability to slow the aging process in mammals; thus, it is hoped the same can be demonstrated in humans.^7,8

A groundbreaking study approved by the Food and Drug Administration (FDA) called Targeting Aging with Metformin (TAME) aims to evaluate metformin’s ability to slow aging. The clinical trials will include 3,000 people, who either suffer from or have a high risk of developing diseases, tracked over a course of six years – where half of the participants will receive metformin, and the other half will receive a placebo.⁶ Success of the study will be determined by whether the drug slows down the onset of major age-related chronic diseases – such as cardiovascular disease, cancer and dementia.⁶ Additionally, metformin helps the body repair DNA, which is critical in cancer prevention.

Longevity-signaling molecules in human cells, known as mTOR and AMPK, are increased when taking metformin – which helps to reduce fat and sugar storage that support the cells function youthfully, and prevent the early stages in atherosclerosis development (hardening of the arteries).⁶ Treatment with metformin can activate AMPK by cleaning up proteins in the brain that can cause brain cells to die.⁶ Build-up of brain proteins can cause brain cell death and abnormality in neuro-degenerative diseases. These affects have been demonstrated in animal and laboratory studies. As humans age, AMPK activity decreases which can make the body more susceptible to disease.^6,9

Underwriting Impact

Although further research is needed to validate the specific impact of metformin on the human body, scientists and physicians hope additional studies will provide further insight and understanding into how this medication could positively impact longevity. Underwriters in all lines of business should be aware of how treatment with the drug may impact mortality and potentially improve the quality of life in old age for patients across the United States.